Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14437215 | 1.00 | SRD5A1 (0.45) | SRD5A1CAMK2APGRGFRA3RET | |
| SCHEMBL2435536 | 1.00 | SRD5A1 (0.45) | SRD5A1CAMK2APGRGFRA3RET | |
| SCHEMBL3202300 | 1.00 | SRD5A1 (0.45) | SRD5A1CAMK2APGRGFRA3RET | |
| SCHEMBL31650212 | 0.89 | CAMK2A (0.50) | SRD5A1CAMK2APGRKDM1ASLC6A4 | |
| SCHEMBL7679993 | 0.89 | CAMK2A (0.50) | SRD5A1CAMK2APGRKDM1ASLC6A4 | |
| SCHEMBL16794356 | 0.87 | CAMK2A (0.49) | SRD5A1CAMK2APGRKDM1ASLC6A4 | |
| SCHEMBL9276752 | 0.84 | HTR2A (0.46) | SRD5A1CAMK2AKDM1AHTR2AHTR2C | |
| SCHEMBL1576024 | 0.84 | HTR2A (0.46) | SRD5A1CAMK2AKDM1AHTR2AHTR2C | |
| SCHEMBL3638981 | 0.84 | HTR2A (0.46) | SRD5A1CAMK2AKDM1AHTR2AHTR2C | |
| SCHEMBL27887272 | 0.78 | KDM1A (0.42) | SRD5A1CAMK2AKDM1ASLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4267117-B1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3950676-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND APPLICATION THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620469-A2 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-5338740-A | Angiotensin II receptor antagonists | PFIZER INC. (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0589484-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | disclosed |
| EP-0587194-A1 | 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0587193-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5280032-A | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0357742-B1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES | ROUSSEL-UCLAF (FR) | 1993-06-09 | — | — | EP | disclosed |
| US-5180741-A | Insecticides | ROUSSEL UCLAF (FR) | 1993-01-19 | — | — | US | disclosed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
| EP-0357742-A1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES. | ROUSSEL UCLAF (FR) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989008096-A1 | NEW PYRETHRINOID ESTERS CARRYING AN INDANYL RING, PREPARATION METHOD AND APPLICATION AS PESTICIDES | ROUSSEL-UCLAF (FR) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | SRD5A1 4502/4885CAMK2A 1353/4885PGR 1469/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | SRD5A1 1392/4885CAMK2A 379/4885PGR 1916/4885 |
| US-12595267-B2 | Preparation method for amide compound and application thereof in field of medicine | EZH2, BMI1, EHMT1 | SRD5A1 1222/4885CAMK2A 1545/4885PGR 3104/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | SRD5A1 3449/4885CAMK2A 198/4885PGR 1965/4885 |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | SRD5A1 219/4885CAMK2A 2214/4885PGR 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.